Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

41.21
+0.71001.75%
Post-market: 49.047.83+19.00%17:21 EDT
Volume:1.91M
Turnover:78.72M
Market Cap:3.09B
PE:-11.84
High:42.15
Open:41.65
Low:40.34
Close:40.50
Loading ...

SpringWorks Therapeutics FY Basic EPS USD -3.48

THOMSON REUTERS
·
20 Feb

SpringWorks Therapeutics Shares up 6% Premarket Ahead of Q4 Results

THOMSON REUTERS
·
20 Feb

SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors

TIPRANKS
·
19 Feb

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Zacks
·
14 Feb

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

TipRanks
·
13 Feb

SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
13 Feb

SpringWorks Therapeutics CEO sells $2.56M in common stock

TIPRANKS
·
13 Feb

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon

TIPRANKS
·
13 Feb

SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg

TIPRANKS
·
13 Feb

SpringWorks Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
12 Feb

SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder

MT Newswires Live
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)

TIPRANKS
·
12 Feb

Update: SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Soars 7% After-Hours on FDA Approval for Rare Disease Drug, Merck Acquisition Talks

Stock Track
·
12 Feb

BRIEF-Springworks Therapeutics Announces FDA Approval Of Gomekli (Mirdametinib) For Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
·
12 Feb

SpringWorks Therapeutics confirms FDA approval of Gomekli

TIPRANKS
·
12 Feb

SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Plunges 5.98% After Hours on Profitability Concerns Over Potential Merck Acquisition

Stock Track
·
12 Feb

US FDA approves SpringWorks' genetic disorder drug

Reuters
·
12 Feb

BRIEF-FDA Approved Mirdametinib, For Adult & Pediatric Patients 2 Years Of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable To Complete Resection

Reuters
·
12 Feb